Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
291.41 USD   -0.17%
10:50aRare success for Alzheimer's research unlocks hope for future therapies
RE
03:49aBiogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's Disease
MT
02:25aJapan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Biogen's Latest Data for Alzheimer's Drug Raises Likelihood for Approval, May Lead to 'Significant Stock Upside,' RBC Says

09/28/2022 | 04:29pm EST


ę MT Newswires 2022
All news about BIOGEN INC.
10:50aRare success for Alzheimer's research unlocks hope for future therapies
RE
03:49aBiogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's ..
MT
02:25aJapan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheime..
MT
02:06aJapanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial
RE
11/28Eisai Shares Fall Following Report of Patient Death in Alzheimer's Trial
DJ
11/28Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trial
RE
11/28China Protests Spark Supply Concerns, Weighing on US Equities
MT
11/28China COVID Protests Spark Supply Chain Concerns, Weighing on US Equities
MT
11/28Wall Street ends down sharply, hit by Apple and China worries
RE
11/28Sector Update: Health Care Weakening Near Monday Close
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 069 M - -
Net income 2022 2 904 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 14,3x
Yield 2022 -
Capitalization 41 963 M 41 963 M -
EV / Sales 2022 4,19x
EV / Sales 2023 4,14x
Nbr of Employees 9 610
Free-Float 85,2%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 291,41 $
Average target price 312,23 $
Spread / Average Target 7,14%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP